The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
May 15th 2024
New analyses show adults aged ≥65 years old are at about 30% increased risk of hypertension when diagnosed with diabetes mellitus.
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
New Biomarkers Predict Adverse Events in Cardiac Sarcoidosis
March 23rd 2023Data from a meta-analysis show late gadolinium enhancement (LGE) on cardiac MRI scans and elevated fluorodeoxyglucose (FDG) uptake on PET scans are both strong predictors of major adverse cardiac events for cardiac sarcoidosis.
Failure to Reach LDL-C Target Increases Event Risk Nearly 50% in High-Risk Individuals
March 23rd 2023New research from the Family Heart Foundation indicates high-risk patients who fail to achieve LDL-C targets had a 49% greater rate of cardiovascular events than their counterparts who met LDL-C targets.
Statin Use for ASCVD Prevention Lower Among Black, Hispanic Individuals
March 22nd 2023An analysis of NHANES from 2013 - March 2020 suggest individuals with an indication for statin therapy for primary prevention based on 10-year risk saw low overall use across risk categories and race and ethnicity strata.
AHA/ACC Scientific Statement Reports Benefit of Supervised Exercise Training for HFpEF
March 22nd 2023Released on March 21, the new scientific statement suggests supervised exercise training is safe and may offer substantial improvement in exercise capacity and quality of life, even more than medications, for many patients with heart failure.
Cardiology Case Report: Chest Pain and Syncope
March 12th 2023This case report from Brady Pregerson, MD, features a woman in her late 60s with diabetes mellitus and hypertension presenting to the emergency department with 3 hours of chest heaviness, nausea, and lightheadedness. Can you determine the diagnosis?
Viet Le, PA-C: Value of Disproportionate CAC vs Total CAC for Predicting MACE
March 10th 2023New research from Intermountain Healthcare presented at ACC 2023 examines the prognostic value of disproportionate CAC scores for 1 or more vessels relative to the value of total CAC score for predicting major adverse cardiovascular events.
STELLAR: Sotatercept Improves Function, Alleviates Disease Burden in Pulmonary Arterial Hypertension
March 6th 2023Data from the phase 3 STELLAR trial indicate adding sotatercept to background therapy in PAH was associated with statistically significant improvements in 6-minute walk distance and 8 of the trial's 9 secondary endpoints, including time to death or clinical worsening.
Clyde Yancy, MD: The Prospect of Renal Denervation for Hypertension
March 6th 2023At ACC 2023, HCPLive editorial team sat down with Clyde Yancy, MD, to learn more about his perspective on recent and upcoming advances in cardiovascular care. In this interview, Yancy discusses his perspective on the clinical trial data surrounding renal denervation as a treatment for hypertension.
Linking Flu Vaccine to Cardiovascular Benefit Could Increase Uptake in Older Adults
March 5th 2023In the largest implementation trial ever conducted, new research from the NUDGE FLU trial suggests informing patients of the potential cardiovascular benefits associated with receipt of the flu vaccine could increase uptake among older adults.
Immediate Complete Revascularization Non-Inferior to Staged Procedure in BIOVASC Trial
March 5th 2023In patients with acute coronary syndrome and multi-vessel heart disease, immediate stent treatment was as safe and effective as staged treatment at one year, according to late-breaking data presented at ACC 2023.